Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Immuneering CorporationNASDAQ: IMRX
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 44.01M shares rose 23.9% year over year, behind the +29.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +23.9% toward the trailing-twelve-month pace of +29.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 44.01M USD
- Year-over-year change
- +46.8%
- 4-year CAGR
- +13.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.01M | +46.8% |
| FY2024 | 2024-12-31 | 29.98M | +5.5% |
| FY2023 | 2023-12-31 | 28.42M | +7.7% |
| FY2022 | 2022-12-31 | 26.39M | +0.3% |
| FY2021 | 2021-12-31 | 26.32M | — |
Weighted Avg Shares (Diluted) vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 weighted avg shares (diluted) of 40.92M shares is the 8th highest of the 11 companies compared; the peer median is 63.58M shares.
- Its year-over-year change of +29.8% is the 5th highest of 11, against a peer median of +5.7%.
- Over three fiscal years its annual growth of +18.6% compares with a peer median of +15.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 167.44M | +37.0% | +15.3% | |
| LTM Mar 2026 | 158.02M | +71.7% | +50.6% | |
| LTM Mar 2026 | 126.35M | +0.5% | +0.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | 98.81M | +34.9% | +76.1% |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 62.52M | +2.9% | +23.4% | |
| LTM Mar 2026 | 41.5M | +3.6% | +9.8% | |
| LTM Mar 2026 | 40.92M | +29.8% | +18.6% | |
| LTM Mar 2026 | 27.53M | +1.8% | +0.4% | |
| LTM Mar 2026 | 21.37M | +0.6% | +1.2% | |
| LTM Mar 2026 | 10.86M | +66.5% | +40.6% | |
| Peer median (excluding IMRX) | 63.58M | +5.7% | +15.1% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.08M | 316.95K | 0 | 0 | 0 |
| Cost of Revenue | 1.15M | 158.12K | 0 | 0 | 698.89K |
| Gross Profit | 926.89K | 158.83K | 0 | 0 | (698.89K) |
| Gross Margin | 44.6% | 50.1% | — | — | — |
| Research & Development | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
| Selling, General & Admin | 8.27M | 15.61M | 16.76M | 16.08M | 17.3M |
| Operating Expenses | 34.81M | 51.9M | 58.41M | 64.07M | 58.68M |
| Depreciation & Amortization | 159.07K | 277.25K | 352.08K | 385.07K | 698.89K |
| EBITDA | (33.68M) | (51.47M) | (58.06M) | (63.69M) | (55.33M) |
| EBITDA Margin | -1619.5% | -16238.4% | — | — | — |
| Operating Income | (33.89M) | (51.74M) | (58.41M) | (64.07M) | (59.38M) |
| Operating Margin | -1629.2% | -16325.8% | — | — | — |
| Interest Income | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 42.83K | 1.23M | 4.94M | 3.03M | 3.35M |
| Income Before Tax | (33.84M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Pre-Tax Margin | -1627.1% | -15937.4% | — | — | — |
| Income Tax Expense | (307.49K) | 0 | 0 | 0 | 0 |
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Net Margin | -1612.3% | -15937.3% | — | — | — |
| EPS (Basic) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| EPS (Diluted) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| Weighted Avg Shares | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
| Weighted Avg Shares (Diluted) | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.